Latest Conference Articles

Sacituzumab govitecan may represent a promising option for patients with endocrine resistant, hormone receptor–positive/HER2-negative metastatic breast cancer, according to updated findings from the phase 3 TROPiCs-02 study.

Women with ovarian cancer who received 2 years of maintenance therapy with olaparib experienced a 45% reduction in risk of death, according to a 7-year follow-up.

Donna Catamero, ANP-BC, OCN, CCRC, presented on her experience in expanding satellite clinical trial operations during the International Myeloma Society’s 6th Annual Nursing Symposium.

Findings from the SHAWL study found that sexual dysfunction rates are high among women with lung cancer.

Adding plinabulin to prophylactic pegfilgrastim and antibiotics may help prevent nonengraftment–related febrile neutropenia.

Findings of a retrospective analysis of patients with multiple myeloma showed that the median duration of treatment with daratumumab was 16.6 months.

There is no one-size-fits-all approach to establishing patient-reported outcome measures, according to Hayley Beer, RN.

Sotorasib is often associated with a high rate of hepatotoxic events, most of which are from elevated liver enzymes. However, a lead-in dosing strategy may help address this adverse event and improve patient tolerability.

Daniel J. Verina, DNP, RN, MSN, ACNP-BC, highlights optimal adverse event management with CD38- and SLAM-F7-directed monoclonal antibodies, XPO-1 inhibitors, and CAR T-cell therapies.

A study presented at the 2022 World Conference on Lung Cancer explored the experiences of patients who received checkpoint inhibition therapy for non–small cell lung cancer.

At the international congress on the Future of Breast Cancer West, Hope S. Rugo highlighted the predictive value of residual cancer burden scoring in ongoing research efforts to tailor triple-negative breast cancer treatments.

Aditya Bardia, MD, MPH, discusses ongoing research with oral SERDs, such as elacestrant, and highlights what these agents could represent for patients with estrogen receptor–positive breast cancer.

Leslie Smith, DNP, RN, APRN-CNS, BMTCN, AOCNS, discusses new therapies and treatment selection in the lymphoma landscape.

Laura Wood discusses the successful integration of avelumab, erdafitinib, and enfortumab vedotin-ejfv into oncology nursing practice.

Patients with treatment-naive extensive-stage small cell lung cancer showed encouraging clinical responses with pembrolizumab and etoposide after multiple years of follow-up.

The growing availability of biomarkers has led to the advent of more targeted therapies such as the antibody-drug conjugates (ADCs) fam-trastuzumab deruxtecan-nxki, ado-trastuzumab emtansine, and sacituzumab govitecan-hziy.

Phase 3 findings from the IMpower010 trial show that patients with resected non–small cell lung cancer may achieve an overall survival benefit with atezolizumab.

Stephanie Jackson, DNP, MSN, RN, AOCNP, BMTCN, discusses the trajectory of targeted and CAR T-cell therapies such as ivosidenib and brexucabtagene autoleucel, and what nurses need to know about these treatments to be able to practice at the top of their licensure.

Extended follow-up data from 2 trials confirmed that larotrectinib yielded positive progression-free and overall survival outcomes for patients with NTRK-positive lung cancer.

Phase 1 findings showed a 50% overall response rate among patients with EGFR-mutated non–small cell lung cancer who received amivantamab in combination with lazertinib plus carboplatin and pemetrexed.

Avelumab, erdafitinib, and enfortumab vedotin-ejfv are 3 critical drugs in the treatment of urothelial cancer with distinct safety profiles, according to a presentation at the 6th Annual School of Nursing Oncology™ Meeting.

In a presentation at the 6th Annual School of Nursing Oncology™, Laura Wood, RN, MSN, OCN, highlights key nurse takeaways with VEGF TKI/immune checkpoint inhibitor therapy for patients with renal cell carcinoma.

At the 6th Annual SONO meeting, Kelley A. Rone, DNP, RN, AGNP-C, reviewed evidence supporting molecular testing in patients with colorectal cancer.

Patients with previously treated non–small cell lung cancer experienced a median overall survival of 16.9 months with second- or third-line tislelizumab vs 11.9 months with docetaxel.

Paula Anastasia, RN, MN, AOCN, highlights circumstances in which patients may not be eligible to receive benefit with a PARP inhibitor.

Treatments options for various histologies of leukemia are expanding with FDA approvals for drugs such as the combination of ivosidenib/azacitidine and the CAR T-cell therapy brexucabtagene autoleucel.

Beth Sandy, MSN, CRNP, discusses the application of 2 FDA approved drugs for patients with non–small cell lung cancer and an exon 20 insertion mutation.

At the 6th Annual SONO meeting, Beth Sandy, MSN, CRNP, reviewed available treatment options for patients with identified driver mutations in non–small cell lung cancer.